Compare
Integrated Biopharma Inc vs Xilio Therapeutics, Inc. vs Cumberland Pharmaceuticals Inc vs Aquestive Therapeutics, Inc.
| Latest fiscal year | Integrated Biopharma Inc INBP | Xilio Therapeutics, Inc. XLO | Cumberland Pharmaceuticals Inc CPIX | Aquestive Therapeutics, Inc. AQST |
|---|---|---|---|---|
| Year ended | 2026-06-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $43.87M | $43.77M | $44.52M | $44.55M |
| Revenue growth (YoY) | -19.3% | +589.9% | +17.6% | -22.6% |
| Gross margin | 1.8% | n/a | 85.0% (computed) | 58.3% (computed) |
| Operating margin | -6.2% | -95.9% | -6.3% | -159.5% |
| Net margin | -6.5% | -80.1% | -6.4% | -188.1% |
| Net income | -$2.84M | -$35.04M | -$2.84M | -$83.78M |
| EPS (Diluted) | -$0.09 | -$4.19 | -$0.19 | -$0.78 |
| Operating cash flow | $1.24M | -$4.99M | $4.93M | -$52.43M |
| Free cash flow | $895.0K | -$5.51M | $4.83M | -$52.99M |
| Cash & equivalents | $4.47M | $137.53M | $11.44M | n/a |
| Total assets | $25.34M | $154.69M | $76.82M | $160.43M |
| Total liabilities | $7.67M | $119.41M | $52.28M | $194.09M |
| Shareholders' equity | $17.67M | $35.27M | $24.88M | -$33.66M |
| Return on year-end equity | -16.1% | -99.3% | -11.4% | n/a |
| Shares outstanding | 31.06M | 4.53M | 14.96M | 122.04M |
Revenue, most recent five fiscal years
| Fiscal year | Integrated Biopharma Inc | Xilio Therapeutics, Inc. | Cumberland Pharmaceuticals Inc | Aquestive Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $43.87M Ended 2026-06-30 | $43.77M Ended 2025-12-31 | $44.52M Ended 2025-12-31 | $44.55M Ended 2025-12-31 |
| 1 year earlier | $54.35M Ended 2025-06-30 | $6.34M Ended 2024-12-31 | $37.87M Ended 2024-12-31 | $57.56M Ended 2024-12-31 |
| 2 years earlier | $50.32M Ended 2024-06-30 | n/a | $39.55M Ended 2023-12-31 | $50.58M Ended 2023-12-31 |
| 3 years earlier | $50.67M Ended 2023-06-30 | n/a | $42.01M Ended 2022-12-31 | $47.68M Ended 2022-12-31 |
| 4 years earlier | $56.25M Ended 2022-06-30 | n/a | $35.05M Ended 2021-12-31 | $50.83M Ended 2021-12-31 |